Pathophysiology and medical treatment of carotid artery stenosis

International Journal of Angiology

Volumn 24, Issue 3, 2014, Pages 158-172

  Prasad, Kailash ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

AGE RAGE axis; carotid artery stenosis; epidemiology; oxyradicals; pathogenesis; risk factors; treatment

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR ANTAGONIST; ALCOHOL; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VITAMIN D;

AEROBIC EXERCISE; AGE; ALCOHOL CONSUMPTION; ARTICLE; ATHEROSCLEROSIS; CALORIC RESTRICTION; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; COOKING; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; ENDOTHELIUM CELL; EXERCISE; EXTRACELLULAR MATRIX; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; LIFESTYLE MODIFICATION; LIPID DIET; LOW SATURATED FAT DIET; MACROPHAGE; MORTALITY; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLEIOTROPY; PREVALENCE; PRIORITY JOURNAL; REMISSION; RISK FACTOR; SEX DIFFERENCE; SMOKING; SMOKING CESSATION; SODIUM DIET; T LYMPHOCYTE; WEIGHT CONTROL;

EID: 84941934486     PISSN: 10611711     EISSN: 16155939     Source Type: Journal    
DOI: 10.1055/s-0035-1554911     Document Type: Article

References (233)

1. Feigin V. L., Lawes C. M., Bennett D. A., Anderson C. S. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol: 2003; 2 1 43 53
2. The Intercollegiate Working Party for Stroke National Clinical Guidelines for Stroke. 2nd ed. London Royal College of Physicians: 2004
3. Sacco R. L. Clinical practice. Extracranial carotid stenosis. N Engl J Med: 2001; 345 15 1113 1118
4. Alpert J. N. Extracranial carotid artery. Current concepts of diagnosis and management. Tex Heart Inst J: 1991; 18 2 93 97
5. Clark T. G., Murphy M. F., Rothwell P. M. Long term risks of stroke, myocardial infarction, and vascular death in low risk patients with a non-recent transient ischaemic attack. J Neurol Neurosurg Psychiatry: 2003; 74 5 577 580
6. The European Carotid Surgery Trialists Collaborative Group Risk of stroke in the distribution of an asymptomatic carotid artery. Lancet: 1995; 345 8944 209 212
7. Mineva P. P., Manchev I. C., Hadjiev D. I. Prevalence and outcome of asymptomatic carotid stenosis: a population-based ultrasonographic study. Eur J Neurol: 2002; 9 4 383 388
8. Goessens B. M., Visseren F. L., Algra A., Banga J. D., van der Graaf Y.; SMART Study Group. Screening for asymptomatic cardiovascular disease with noninvasive imaging in patients at high-risk and low-risk according to the European Guidelines on Cardiovascular Disease Prevention: the SMART study. J Vasc Surg: 2006; 43 3 525 532
9. de Weerd M., Greving J. P., Hedblad B., et al. Prevalence of asymptomatic carotid artery stenosis in the general population: an individual participant data meta-analysis. Stroke: 2010; 41 6 1294 1297
10. Barnett H. J., Taylor D. W., Eliasziw M., et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med: 1998; 339 20 1415 1425
11. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study Endarterectomy for asymptomatic carotid artery stenosis. JAMA: 1995; 273 18 1421 1428
12. Fine-Edelstein J. S., Wolf P. A., O'Leary D. H., et al. Precursors of extracranial carotid atherosclerosis in the Framingham Study. Neurology: 1994; 44 6 1046 1050
13. Rockman C. B., Jacobowitz G. R., Gagne P. J., et al. Focused screening for occult carotid artery disease: patients with known heart disease are at high risk. J Vasc Surg: 2004; 39 1 44 51
14. Griffiths P. D., Worthy S., Gholkar A. Incidental intracranial vascular pathology in patients investigated for carotid stenosis. Neuroradiology: 1996; 38 1 25 30
15. Kappelle L. J., Eliasziw M., Fox A. J., Sharpe B. L., Barnett H. J. Importance of intracranial atherosclerotic disease in patients with symptomatic stenosis of the internal carotid artery. The North American Symptomatic Carotid Endarterectomy Trail. Stroke: 1999; 30 2 282 286
16. O'Leary D. H., Polak J. F., Kronmal R. A., Manolio T. A., Burke G. L., Wolfson S. K. Jr.; Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med: 1999; 340 1 14 22
17. Klop R. B., Eikelboom B. C., Taks A. C. Screening of the internal carotid arteries in patients with peripheral vascular disease by colour-flow duplex scanning. Eur J Vasc Surg: 1991; 5 1 41 45
18. Alexandrova N. A., Gibson W. C., Norris J. W., Maggisano R. Carotid artery stenosis in peripheral vascular disease. J Vasc Surg: 1996; 23 4 645 649
19. Ahmed B., Al-Khaffaf H. Prevalence of significant asymptomatic carotid artery disease in patients with peripheral vascular disease: a meta-analysis. Eur J Vasc Endovasc Surg: 2009; 37 3 262 271
20. Bavil A. S., Ghabili K., Daneshmand S. E., et al. Prevalence of significant carotid artery stenosis in Iranian patients with peripheral arterial disease. Vasc Health Risk Manag: 2011; 7 629 632
21. Tanimoto S., Ikari Y., Tanabe K., et al. Prevalence of carotid artery stenosis in patients with coronary artery disease in Japanese population. Stroke: 2005; 36 10 2094 2098
22. Kallikazaros I., Tsioufis C., Sideris S., Stefanadis C., Toutouzas P. Carotid artery disease as a marker for the presence of severe coronary artery disease in patients evaluated for chest pain. Stroke: 1999; 30 5 1002 1007
23. Steinvil A., Sadeh B., Arbel Y., et al. Prevalence and predictors of concomitant carotid and coronary artery atherosclerotic disease. J Am Coll Cardiol: 2011; 57 7 779 783
24. Qureshi A. I., Alexandrov A. V., Tegeler C. H., Hobson R. W. II, Dennis Baker J., Hopkins L. N.; American Society of Neuroimaging; Society of Vascular and Interventional Neurology. Guidelines for screening of extracranial carotid artery disease: a statement for healthcare professionals from the multidisciplinary practice guidelines committee of the American Society of Neuroimaging; cosponsored by the Society of Vascular and Interventional Neurology. J Neuroimaging: 2007; 17 1 19 47
25. Mathiesen E. B., Joakimsen O., Bonaa K. H. Prevalence of and risk factors associated with carotid artery stenosis: the Tromso Study. Cerebrovasc Dis: 2001; 12 1 44 51
26. Prasad K. Pathophysiology of atherosclerosis. In: Chang J. B., Olsen E. R., Prasad K., Sumpio B. E., eds. Textbook of Angiology. New York, NY Springer Verlag: 2000; 85 105
27. Yamazaki M., Uchiyama S. Pathophysiology of carotid stenosis [in Japanese]. Brain Nerve: 2010; 62 12 1269 1275
28. Galis Z. S., Sukhova G. K., Lark M. W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest: 1994; 94 6 2493 2503
29. Naghavi M., Libby P., Falk E., et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation: 2003; 108 14 1664 1672
30. Wahlgren C. M., Zheng W., Shaalan W., Tang J., Bassiouny H. S. Human carotid plaque calcification and vulnerability. Relationship between degree of plaque calcification, fibrous cap inflammatory gene expression and symptomatology. Cerebrovasc Dis: 2009; 27 2 193 200
31. Shaalan W. E., Cheng H., Gewertz B., et al. Degree of carotid plaque calcification in relation to symptomatic outcome and plaque inflammation. J Vasc Surg: 2004; 40 2 262 269
32. Ku D. N., Giddens D. P., Zarins C. K., Glagov S. Pulsatile flow and atherosclerosis in the human carotid bifurcation. Positive correlation between plaque location and low oscillating shear stress. Arteriosclerosis: 1985; 5 3 293 302
33. Zarins C. K., Giddens D. P., Bharadvaj B. K., Sottiurai V. S., Mabon R. F., Glagov S. Carotid bifurcation atherosclerosis. Quantitative correlation of plaque localization with flow velocity profiles and wall shear stress. Circ Res: 1983; 53 4 502 514
34. Lind L., Andersson J., Larsson A., Sandhagen B. Shear stress in the common carotid artery is related to both intima-media thickness and echogenecity. The Prospective Investigation of the Vasculature in Uppsala Seniors study. Clin Hemorheol Microcirc: 2009; 43 4 299 308
35. Mauriello A., Sangiorgi G. M., Virmani R., et al. A pathobiologic link between risk factors profile and morphological markers of carotid instability. Atherosclerosis: 2010; 208 2 572 580
36. Prasad K., Kalra J. Oxygen free radicals and hypercholesterolemic atherosclerosis: effect of vitamin E. Am Heart J: 1993; 125 4 958 973
37. Prasad K. Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Circulation: 1999; 99 10 1355 1362
38. Prasad K., Kalra J., Lee P. Oxygen free radicals as a mechanism of hypercholesterolemic atherosclerosis: effect of probucol. Int J Angiol: 1994; 3 100 112
39. Steinberg D. Antioxidants and atherosclerosis. A current assessment. Circulation: 1991; 84 3 1420 1425
40. Steinberg D. Antioxidants in the prevention of human atherosclerosis. Summary of the proceedings of a National Heart, Lung, and Blood Institute Workshop: September 5-6, 1991, Bethesda, Maryland. Circulation: 1992; 85 6 2337 2344
41. Willam C., Schindler R., Frei U., Eckardt K. U. Increases in oxygen tension stimulate expression of ICAM-1 and VCAM-1 on human endothelial cells. Am J Physiol: 1999; 276 6 Pt 2 H2044 H2052
42. Chiu J. J., Wung B. S., Shyy J. Y-J, Hsieh H. J., Wang D. L. Reactive oxygen species are involved in shear stress-induced intercellular adhesion molecule-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol: 1997; 17 12 3570 3577
43. Fraticelli A., Serrano C. V. Jr, Bochner B. S., Capogrossi M. C., Zweier J. L. Hydrogen peroxide and superoxide modulate leukocyte adhesion molecule expression and leukocyte endothelial adhesion. Biochim Biophys Acta: 1996; 1310 3 251 259
44. Martin A., Foxall T., Blumberg J. B., Meydani M. Vitamin E inhibits low-density lipoprotein-induced adhesion of monocytes to human aortic endothelial cells in vitro. Arterioscler Thromb Vasc Biol: 1997; 17 3 429 436
45. Cushing S. D., Berliner J. A., Valente A. J., et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A: 1990; 87 13 5134 5138
46. Steinberg D. Oxidized low density lipoprotein-an extreme example of lipoprotein heterogeneity. Isr J Med Sci: 1996; 32 6 469 472
47. Wang G. P., Deng Z. D., Ni J., Qu Z. L. Oxidized low density lipoprotein and very low density lipoprotein enhance expression of monocyte chemoattractant protein-1 in rabbit peritoneal exudate macrophages. Atherosclerosis: 1997; 133 1 31 36
48. Navab M., Imes S. S., Hama S. Y., et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest: 1991; 88 6 2039 2046
49. Hashimoto K., Kataoka N., Nakamura E., Tsujioka K., Kajiya F. Oxidized LDL specifically promotes the initiation of monocyte invasion during transendothelial migration with upregulated PECAM-1 and downregulated VE-cadherin on endothelial junctions. Atherosclerosis: 2007; 194 2 e9 e17
50. Goldstein J. L., Ho Y. K., Basu S. K., Brown M. S. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A: 1979; 76 1 333 337
51. Nagy L., Tontonoz P., Alvarez J. G., Chen H., Evans R. M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell: 1998; 93 2 229 240
52. Henriksen T., Mahoney E. M., Steinberg D. Enhanced macrophage degradation of biological modified low density lipoprotein. Atherosclerosis: 1983; 3 2 149 159
53. Rajagopalan S., Meng X. P., Ramasamy S., Harrison D. G., Galis Z. S. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest: 1996; 98 11 2572 2579
54. Phan S. H., McGarry B. M., Loeffler K. M., Kunkel S. L. Regulation of macrophage-derived fibroblast growth factor release by arachidonate metabolites. J Leukoc Biol: 1987; 42 2 106 113
55. Raitakari O. T., Juonala M., Kähönen M., et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA: 2003; 290 17 2277 2283
56. Warnholtz A., Wendt M., August M., Münzel T. Clinical aspects of reactive oxygen and nitrogen species. Biochem Soc Symp: 2004; 71 71 121 133
57. White C. R., Darley-Usmar V., Berrington W. R., et al. Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc Natl Acad Sci U S A: 1996; 93 16 8745 8749
58. Liu H-R, Tao L., Gao E., et al. Rosiglitazone inhibits hypercholesterolaemia-induced myeloperoxidase upregulation- A novel mechanism for the cardioprotective effects of PPAR agonists. Cardiovasc Res: 2009; 81 2 344 352
59. Zhu X., Lee J. Y., Timmins J. M., et al. Increased cellular free cholesterol in macrophage specific Abca 1 knock-out mice enhances proinflammatory response of macrophage. J Biol Chem: 2008; 283 2930 2294
60. Yang D., Elner S. G., Bian Z. M., Till G. O., Petty H. R., Elner V. M. Pro-inflammatory cytokines increase reactive oxygen species through mitochondria and NADPH oxidase in cultured RPE cells. Exp Eye Res: 2007; 85 4 462 472
61. Prasad K., Mantha S. V., Kalra J., Lee P. Prevention of hypercholesterolemic atherosclerosis by garlic, an antioxidant. J Cardiovasc Pharmacol Therapeut: 1997; 2 4 309 319
62. Prasad K. Hypocholesterolemic and antiatherosclerotic effect of flax lignan complex isolated from flaxseed. Atherosclerosis: 2005; 179 2 269 275
63. O'Donnell R. W., Johnson D. K., Ziegler L. M., DiMattina A. J., Stone R. I., Holland J. A. Endothelial NADPH oxidase: mechanism of activation by low-density lipoprotein. Endothelium: 2003; 10 6 291 297
64. Heinloth A., Heermeier K., Raff U., Wanner C., Galle J. Stimulation of NADPH oxidase by oxidized low-density lipoprotein induces proliferation of human vascular endothelial cells. J Am Soc Nephrol: 2000; 11 10 1819 1825
65. Smalley D. M., Lin J. H., Curtis M. L., Kobari Y., Stemerman M. B., Pritchard K. A. Jr. Native LDL increases endothelial cell adhesiveness by inducing intercellular adhesion molecule-1. Arterioscler Thromb Vasc Biol: 1996; 16 4 585 590
66. Allen S., Khan S., Al-Mohanna F., Batten P., Yacoub M. Native low density lipoprotein-induced calcium transients trigger VCAM-1 and E-selectin expression in cultured human vascular endothelial cells. J Clin Invest: 1998; 101 5 1064 1075
67. Zhu H. L., Xia M., Hou M. J., Tang Z. H., Zheng P. Y., Ling W. H. Effects of LOX-1 on expression of adhesion molecules induced by ox-LDL in HUVECs [in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi: 2005; 33 8 743 747
68. Peshavariya H., Dusting G. J., Di Bartolo B., Rye K. A., Barter P. J., Jiang F. Reconstituted high-density lipoprotein suppresses leukocyte NADPH oxidase activation by disrupting lipid rafts. Free Radic Res: 2009; 43 8 772 782
69. Cockerill G. W., Rye K. A., Gamble J. R., Vadas M. A., Barter P. J. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol: 1995; 15 11 1987 1994
70. Calabresi L., Franceschini G., Sirtori C. R., et al. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem Biophys Res Commun: 1997; 238 1 61 65
71. Mackness B., Hine D., Liu Y., Mastorikou M., Mackness M. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun: 2004; 318 3 680 683
72. Eggesbo J. B., Hjermann I., Hostmark A. T., Joo G. B., Kierulf P. Lipopolysaccharide-induced monocyte procoagulant activity, fibrinopeptide A, and PAI-I levels in persons with high or low levels of HDL-lipoprotein. Thromb Res: 1993; 70 2 161 171
73. Tölle M., Pawlak A., Schuchardt M., et al. HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler Thromb Vasc Biol: 2008; 28 8 1542 1548
74. Kim Y. S., Sung H. J., Son S. J., et al. Triglyceride (TG) down-regulates expression of MCP-1 and CCR2 in PMA-derived THP-1 macrophages. Genes and Genomics: 2013; 35 1 125 130
75. Packard C. J. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans: 2003; 31 Pt 5 1066 1069
76. Wang L., Gill R., Pedersen T. L., Higgins L. J., Newman J. W., Rutledge J. C. Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. J Lipid Res: 2009; 50 2 204 213
77. Eiselein L., Wilson D. W., Lamé M. W., Rutledge J. C. Lipolysis products from triglyceride-rich lipoproteins increase endothelial permeability, perturb zonula occludens-1 and F-actin, and induce apoptosis. Am J Physiol Heart Circ Physiol: 2007; 292 6 H2745 H2753
78. Wang Y. I., Bettaieb A., Sun C., et al. Triglyceride-rich lipoprotein modulates endothelial vascular cell adhesion molecule (VCAM)-1 expression via differential regulation of endoplasmic reticulum stress. PLoS ONE: 2013; 8 10 e78322
79. Skartlien A. H., Lyberg-Beckmann S., Holme I., Hjermann I., Prydz H. Effect of alteration in triglyceride levels on factor VII-phospholipid complexes in plasma. Arteriosclerosis: 1989; 9 6 798 801
80. Negri M., Arigliano P. L., Talamini G., Carlini S., Manzato F., Bonadonna G. Levels of plasma factor VII and factor VII activated forms as a function of plasma triglyceride levels. Atherosclerosis: 1993; 99 1 55 61
81. Simpson H. CR, Mann J. I., Meade T. W., Chakrabarti R., Stirling Y., Woolf L. Hypertriglyceridaemia and hypercoagulability. Lancet: 1983; 1 8328 786 790
82. Hamsten A., Wiman B., de Faire U., Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med: 1985; 313 25 1557 1563
83. Vanschoonbeek K., Feijge M. A., Saris W. H., de Maat M. P., Heemskerk J. W. Plasma triacylglycerol and coagulation factor concentrations predict the anticoagulant effect of dietary fish oil in overweight subjects. J Nutr: 2007; 137 1 7 13
84. Kitiyakara C., Wilcox C. S. Antioxidants for hypertension. Curr Opin Nephrol Hypertens: 1998; 7 5 531 538
85. Zalba G., Beaumont F. J., San José G., et al. Vascular NADH/NADPH oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats. Hypertension: 2000; 35 5 1055 1061
86. Wu R., Millette E., Wu L., de Champlain J. Enhanced superoxide anion formation in vascular tissues from spontaneously hypertensive and desoxycorticosterone acetate-salt hypertensive rats. J Hypertens: 2001; 19 4 741 748
87. Touyz R. M., Schiffrin E. L. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol: 2004; 122 4 339 352
88. Welch W. J. Intrarenal oxygen and hypertension. Clin Exp Pharmacol Physiol: 2006; 33 10 1002 1005
89. Redón J., Oliva M. R., Tormos C., et al. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension: 2003; 41 5 1096 1101
90. Manning R. D. Jr, Meng S., Tian N. Renal and vascular oxidative stress and salt-sensitivity of arterial pressure. Acta Physiol Scand: 2003; 179 3 243 250
91. Houston M. C. Nutraceuticals, vitamins, antioxidants, and minerals in the prevention and treatment of hypertension. Prog Cardiovasc Dis: 2005; 47 6 396 449
92. Lacy F., Kailasam M. T., O'Connor D. T., Schmid-Schönbein G. W., Parmer R. J. Plasma hydrogen peroxide production in human essential hypertension: role of heredity, gender, and ethnicity. Hypertension: 2000; 36 5 878 884
93. Sagar S., Kallo I. J., Kaul N., Ganguly N. K., Sharma B. K. Oxygen free radicals in essential hypertension. Mol Cell Biochem: 1992; 111 1-2 103 108
94. Yasunari K., Maeda K., Nakamura M., Yoshikawa J. Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reacting protein. Hypertension: 2002; 39 3 777 780
95. Fortuño A., Oliván S., Beloqui O., et al. Association of increased phagocytic NADPH oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension. J Hypertens: 2004; 22 11 2169 2175
96. Higashi Y., Sasaki S., Nakagawa K., Matsuura H., Oshima T., Chayama K. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med: 2002; 346 25 1954 1962
97. Lip G. Y., Edmunds E., Nuttall S. L., Landray M. J., Blann A. D., Beevers D. G. Oxidative stress in malignant and non-malignant phase hypertension. J Hum Hypertens: 2002; 16 5 333 336
98. Harrison D. G., Gongora M. C. Oxidative stress and hypertension. Med Clin North Am: 2009; 93 3 621 635
99. Vaziri N. D. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens: 2004; 13 1 93 99
100. Addabbo F., Montagnani M., Goligorsky M. S. Mitochondria and reactive oxygen species. Hypertension: 2009; 53 6 885 892
101. Bautista L. E., Vera L. M., Arenas I. A., Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-α) and essential hypertension. J Hum Hypertens: 2005; 19 2 149 154
102. Chae C. U., Lee R. T., Rifai N., Ridker P. M. Blood pressure and inflammation in apparently healthy men. Hypertension: 2001; 38 3 399 403
103. Dalekos G. N., Elisaf M., Bairaktari E., Tsolas O., Siamopoulos K. C. Increased serum levels of interleukin-1β in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients? J Lab Clin Med: 1997; 129 3 300 308
104. Lusis A. J. Atherosclerosis. Nature: 2000; 407 6801 233 241
105. Shalia K. K., Mashru M. R., Vasvani J. B., Mokal R. A., Mithbawkar S. M., Thakur P. K. Circulating levels of cell adhesion molecules in hypertension. Indian J Clin Biochem: 2009; 24 4 388 397
106. Malmqvist K., Wallén H. N., Held C., Kahan T. Soluble cell adhesion molecules in hypertensive concentric left ventricular hypertrophy. J Hypertens: 2002; 20 8 1563 1569
107. Itoh T., Nagaya N., Ishibashi-Ueda H., et al. Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension. Respirology: 2006; 11 2 158 163
108. Koh K. K., Ahn J. Y., Han S. H., et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol: 2003; 42 5 905 910
109. Deo R., Khera A., McGuire D. K., et al. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol: 2004; 44 9 1812 1818
110. Parissis J. T., Venetsanou K. F., Kalantzi M. V., Mentzikof D. D., Karas S. M. Serum profiles of granulocyte-macrophage colony-stimulating factor and C-C chemokines in hypertensive patients with or without significant hyperlipidemia. Am J Cardiol: 2000; 85 6 777 779, A9
111. Tell G. S., Polak J. F., Ward B. J., Kittner S. J., Savage P. J., Robbins J.; The Cardiovascular Health Study (CHS) Collaborative Research Group. Relation of smoking with carotid artery wall thickness and stenosis in older adults. The Cardiovascular Health Study. Circulation: 1994; 90 6 2905 2908
112. Mast H., Thompson J. LP, Lin I-F., et al. Cigarette smoking as a determinant of high-grade carotid artery stenosis in Hispanic, black, and white patients with stroke or transient ischemic attack. Stroke: 1998; 29 5 908 912
113. Kalra J., Chaudhary A. K., Prasad K. Increased production of oxygen free radicals in cigarette smokers. Int J Exp Pathol: 1991; 72 1 1 7
114. Pryor W. A., Stone K. Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann N Y Acad Sci: 1993; 686 12 27, discussion 27-28
115. Kayyali U. S., Budhiraja R., Pennella C. M., et al. Upregulation of xanthine oxidase by tobacco smoke condensate in pulmonary endothelial cells. Toxicol Appl Pharmacol: 2003; 188 1 59 68
116. Nicholl I. D., Bucala R. Advanced glycation endproducts and cigarette smoking. Cell Mol Biol (Noisy-le-grand): 1998; 44 7 1025 1033
117. Cerami C., Founds H., Nicholl I., et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A: 1997; 94 25 13915 13920
118. Shah A. A., Khand F., Khand T. U. Effect of smoking on serum xanthine oxidase, malondialdehyde, ascorbic acid and α-tocopherol levels in healthy male subjects. Pak J Med Sci: 2015; 31 1 146 149
119. Totti N. III, McCusker K. T., Campbell E. J., Griffin G. L., Senior R. M. Nicotine is chemotactic for neutrophils and enhances neutrophil responsiveness to chemotactic peptides. Science: 1984; 223 4632 169 171
120. Assmann G., Schulte H., Schriewer H. The effects of cigarette smoking on serum levels of HDL cholesterol and HDL apolipoprotein A-I. Findings of a prospective epidemiological study on employees of several companies in Westphalia, West Germany. J Clin Chem Clin Biochem: 1984; 22 6 397 402
121. Kokaze A., Ishikawa M., Matsunaga N., et al. Difference in effects of cigarette smoking or alcohol consumption on serum non-high-density lipoprotein cholesterol levels is related to mitochondrial DNA 5178 C/A polymorphism in middle-aged Japanese men: a cross-sectional study. J Physiol Anthropol: 2014; 33 1
122. McDermott D. H., Yang Q., Kathiresan S., et al. CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation: 2005; 112 8 1113 1120
123. Prasad K., Dhar I. Role of advanced glycation end products and its receptors in the pathogenesis of cigarette smoke-induced cardiovascular disease. Int J Angiol: 2015; 24 2 75 80
124. Prasad K. Soluble receptor for advanced glycation end products (sRAGE) and cardiovascular disease. Int J Angiol: 2006; 15 57 68
125. Schmidt A. M., Yan S. D., Yan S. F., Stern D. M. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta: 2000; 1498 2-3 99 111
126. Schmidt A. M., Yan S. D., Wautier J. L., Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res: 1999; 84 5 489 497
127. Braquet P., Hosford D., Braquet M., Bourgain R., Bussolino F. Role of cytokines and platelet-activating factor in microvascular immune injury. Int Arch Allergy Appl Immunol: 1989; 88 1-2 88 100
128. Yuo A., Kitagawa S., Kasahara T., Matsushima K., Saito M., Takaku F. Stimulation and priming of human neutrophils by interleukin-8: cooperation with tumor necrosis factor and colony-stimulating factors. Blood: 1991; 78 10 2708 2714
129. Anil S., Preethanath R. S., Alasqah M., Mokeem S. A., Anand P. S. Increased levels of serum and gingival crevicular fluid monocyte chemoattractant protein-1 in smokers with periodontitis. J Periodontol: 2013; 84 9 e23 e28
130. Köttstorfer J., Kaiser G., Thomas A., et al. The influence of non-osteogenic factors on the expression of M-CSF and VEGF during fracture healing. Injury: 2013; 44 7 930 934
131. Al-Ghurabi B. H. Impact of smoking on the IL-β, IL-8, IL-10, IL-17 and TNF-α production in chronic periodontitis patients. J Asian Sci Res.: 2013; 3 5 462 470
132. Scott D. A., Palmer R. M. The influence of tobacco smoking on adhesion molecule profiles. Tob Induc Dis: 2002; 1 1 7 25
133. Cavusoglu Y., Timuralp B., Us T., et al. Cigarette smoking increases plasma concentrations of vascular cell adhesion molecule-1 in patients with coronary artery disease. Angiology: 2004; 55 4 397 402
134. Schwartz C. J., Valente A. J., Sprague E. A., Kelley J. L., Cayatte A. J., Rozek M. M. Pathogenesis of the atherosclerotic lesion. Implications for diabetes mellitus. Diabetes Care: 1992; 15 9 1156 1167
135. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes: 1999; 48 5 937 942
136. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med: 1993; 329 14 977 986
137. Turrens J. F. Mitochondrial formation of reactive oxygen species. J Physiol: 2003; 552 Pt 2 335 344
138. Bonnefont-Rousselot D. Glucose and reactive oxygen species. Curr Opin Clin Nutr Metab Care: 2002; 5 5 561 568
139. Inoguchi T., Li P., Umeda F., et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes: 2000; 49 11 1939 1945
140. Banerjee D., Sharma P. Dual effects of glucose on macrophage NADPH-oxidase activity: a possible link between diabetes and tuberculosis. Oxid Antioxid Med Sci: 2012; 1 2 91 96
141. Wolff S. P. Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br Med Bull: 1993; 49 3 642 652
142. Elrick H., Stimmler L., Hlad C. J. Jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab: 1964; 24 1076 1082
143. May J. M., de Haën C. Insulin-stimulated intracellular hydrogen peroxide production in rat epididymal fat cells. J Biol Chem: 1979; 254 7 2214 2220
144. Goldstein B. J., Mahadev K., Wu X., Zhu L., Motoshima H. Role of insulin-induced reactive oxygen species in the insulin signaling pathway. Antioxid Redox Signal: 2005; 7 7-8 1021 1031
145. Maples K. R., Mason R. P. Free radical metabolite of uric acid. J Biol Chem: 1988; 263 4 1709 1712
146. Vásquez-Vivar J., Santos A. M., Junqueira V. B., Augusto O. Peroxynitrite-mediated formation of free radicals in human plasma: EPR detection of ascorbyl, albumin-thiyl and uric acid-derived free radicals. Biochem J: 1996; 314 Pt 3 869 876
147. Bagnati M., Perugini C., Cau C., Bordone R., Albano E., Bellomo G. When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid. Biochem J: 1999; 340 Pt 1 143 152
148. Bucala R., Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol: 1992; 23 1 34
149. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med: 1988; 318 20 1315 1321
150. Vlassara H., Bucala R., Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest: 1994; 70 2 138 151
151. Reddy S., Bichler J., Wells-Knecht K. J., Thorpe S. R., Baynes J. W. N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry: 1995; 34 34 10872 10878
152. Brownlee M., Vlassara H., Cerami A. Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes: 1985; 34 9 938 941
153. Brownlee M., Vlassara H., Kooney A., Ulrich P., Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science: 1986; 232 4758 1629 1632
154. Bucala R., Makita Z., Koschinsky T., Cerami A., Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A: 1993; 90 14 6434 6438
155. Steinbrecher U. P., Witztum J. L. Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes: 1984; 33 2 130 134
156. Neeper M., Schmidt A. M., Brett J., et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem: 1992; 267 21 14998 15004
157. Schmidt A. M., Yan S. D., Yan S. F., Stern D. M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest: 2001; 108 7 949 955
158. Tam X. HL, Shiu S. WM, Leng L., Bucala R., Betteridge D. J., Tan K. CB. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes. Clin Sci (Lond): 2011; 120 2 81 89
159. Yonekura H., Yamamoto Y., Sakurai S., et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J: 2003; 370 Pt 3 1097 1109
160. Koyama H., Shoji T., Yokoyama H., et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol: 2005; 25 12 2587 2593
161. Koyama H., Yamamoto H., Nishizawa Y. RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol Med: 2007; 13 11-12 625 635
162. Park L., Raman K. G., Lee K. J., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med: 1998; 4 9 1025 1031
163. Tanji N., Markowitz G. S., Fu C., et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol: 2000; 11 9 1656 1666
164. Brett J., Schmidt A. M., Yan S. D., et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol: 1993; 143 6 1699 1712
165. Wautier M. P., Chappey O., Corda S., Stern D. M., Schmidt A. M., Wautier J. L. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab: 2001; 280 5 E685 E694
166. Hofmann M. A., Drury S., Fu C., et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell: 1999; 97 7 889 901
167. Reznikov L. L., Waksman J., Azam T., et al. Effect of advanced glycation end products on endotoxin-induced TNF-alpha, IL-1beta and IL-8 in human peripheral blood mononuclear cells. Clin Nephrol: 2004; 61 5 324 336
168. Schmidt A. M., Hori O., Chen J. X., et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest: 1995; 96 3 1395 1403
169. Wautier J. L., Zoukourian C., Chappey O., et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest: 1996; 97 1 238 243
170. Esposito C., Gerlach H., Brett J., Stern D., Vlassara H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med: 1989; 170 4 1387 1407
171. Schmidt A. M., Yan S. D., Brett J., Mora R., Nowygrod R., Stern D. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest: 1993; 91 5 2155 2168
172. Vlassara H., Fuh H., Makita Z., Krungkrai S., Cerami A., Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci U S A: 1992; 89 24 12043 12047
173. Vlassara H., Brownlee M., Manogue K. R., Dinarello C. A., Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science: 1988; 240 4858 1546 1548
174. Kirstein M., Brett J., Radoff S., Ogawa S., Stern D., Vlassara H. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci U S A: 1990; 87 22 9010 9014
175. Kirstein M., Aston C., Hintz R., Vlassara H. Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. J Clin Invest: 1992; 90 2 439 446
176. Klein R. L., Laimins M., Lopes-Virella M. F. Isolation, characterization, and metabolism of the glycated and nonglycated subfractions of low-density lipoproteins isolated from type I diabetic patients and nondiabetic subjects. Diabetes: 1995; 44 9 1093 1098
177. Sakata N., Meng J., Takebayashi S. Effects of advanced glycation end products on the proliferation and fibronectin production of smooth muscle cells. J Atheroscler Thromb: 2000; 7 3 169 176
178. Sakaguchi T., Yan S. F., Yan S. D., et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest: 2003; 111 7 959 972
179. Zhou Z., Wang K., Penn M. S., et al. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation: 2003; 107 17 2238 2243
180. Wendt T. M., Bucciarelli L. G., Lu X., et al. Accelerated atherosclerosis and vascular inflammation develop in apo-E null mice with type 2 diabetes. Circulation: 2000; 102 (Suppl): II-231 [abstract]
181. Kislinger T., Tanji N., Wendt T., et al. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol: 2001; 21 6 905 910
182. McNair E. D., Wells C. R., Qureshi A. M., et al. Low levels of soluble receptor for advanced glycation end products in non-ST elevation myocardial infarction patients. Int J Angiol: 2009; 18 4 187 192
183. McNair E. D., Wells C. R., Mabood Qureshi A., et al. Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention. Clin Cardiol: 2010; 33 11 678 685
184. Xia P., Inoguchi T., Kern T. S., Engerman R. L., Oates P. J., King G. L. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes: 1994; 43 9 1122 1129
185. Koya D., King G. L. Protein kinase C activation and the development of diabetic complications. Diabetes: 1998; 47 6 859 866
186. Kawano M., Koshikawa T., Kanzaki T., Morisaki N., Saito Y., Yoshida S. Diabetes mellitus induces accelerated growth of aortic smooth muscle cells: association with overexpression of PDGF β-receptors. Eur J Clin Invest: 1993; 23 2 84 90
187. Nabel E. G., Shum L., Pompili V. J., et al. Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci U S A: 1993; 90 22 10759 10763
188. Bloomgarden Z. T. Obesity and diabetes. Diabetes Care: 2000; 23 10 1584 1590
189. Kotsis V., Stabouli S., Papakatsika S., Rizos Z., Parati G. Mechanisms of obesity-induced hypertension. Hypertens Res: 2010; 33 5 386 393
190. Kahn S. E., Hull R. L., Utzschneider K. M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature: 2006; 444 7121 840 846
191. Rost N. S., Wolf P. A., Kase C. S., et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke: 2001; 32 11 2575 2579
192. Mullenix P. S., Steele S. R., Martin M. J., Starnes B. W., Andersen C. A. C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis. Arch Surg: 2007; 142 11 1066 1071
193. Xiao-Jun W., Wei L., Dong-Yang X., Yi-ming Z., Dang-Ming X., Xiao-Jun W. Correlation study of carotid atherosclerosis and serum high sensitivity C - reactive protein levels in elderly hypertensive patients. Heart: 2012; 98 02 E1 E319
194. Gröschel K., Ernemann U., Larsen J., et al. Preprocedural C-reactive protein levels predict stroke and death in patients undergoing carotid stenting. AJNR Am J Neuroradiol: 2007; 28 9 1743 1746
195. Prasad K. C-reactive protein increases oxygen radical generation by neutrophils. J Cardiovasc Pharmacol Ther: 2004; 9 3 203 209
196. Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev: 2006; 24 1 33 50
197. Hobson R. W. II, Mackey W. C., Ascher E., et al. Society for Vascular Surgery. Management of atherosclerotic carotid artery disease: clinical practice guidelines of the Society for Vascular Surgery. J Vasc Surg: 2008; 48 2 480 486
198. Herder M., Arntzen K. A., Johnsen S. H., Eggen A. E., Mathiesen E. B. Long-term use of lipid-lowering drugs slows progression of carotid atherosclerosis: the Tromso study 1994 to 2008. Arterioscler Thromb Vasc Biol: 2013; 33 4 858 862
199. Prasad K. Do statins have a role in reduction/prevention of post-PCI restenosis? Cardiovasc Ther: 2013; 31 1 12 26
200. Liao J. K., Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol: 2005; 45 89 118
201. Cuspidi C., Negri F., Giudici V., Capra A., Sala C. Effects of antihypertensive drugs on carotid intima-media thickness: Focus on angiotensin II receptor blockers. A review of randomized, controlled trials. Integr Blood Press Control: 2009; 2 1 8
202. Johnson C. T., Brewster L. P. Carotid artery intima-media thickness and the renin-angiotensin system. Hosp Pract (1995): 2013; 41 2 54 61
203. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. U.S. Department of Health and Human Services. National Heart, Lung, and Blood Institute; 2004
204. Khan N. A., McAlister F. A., Lewanczuk R. Z., et al. The 2005 Canadian Hypertention Education Program recommendation for the management of hypertension: part II-Therapy. Can J Cardiol: 2006; 22 7 583 593
205. Mazzone T. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention. Am J Med: 2007; 120 (9, Suppl 2): S26 S32
206. Mazzone T., Meyer P. M., Feinstein S. B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA: 2006; 296 21 2572 2581
207. Schindler T. H., Cadenas J., Facta A. D., et al. Improvement in coronary endothelial function is independently associated with a slowed progression of coronary artery calcification in type 2 diabetes mellitus. Eur Heart J: 2009; 30 24 3064 3073
208. Bianchi C., Miccoli R., Daniele G., Penno G., Del Prato S. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes. Diabetes Care: 2009; 32 02 S342 S348
209. Esposito K., Giugliano D., Nappo F., Marfella R.; Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation: 2004; 110 2 214 219
210. Vlassara H., Cai W., Crandall J., et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A: 2002; 99 24 15596 15601
211. Birlouez-Aragon I., Saavedra G., Tessier F. J., et al. A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases. Am J Clin Nutr: 2010; 91 5 1220 1226
212. Kass D. A., Shapiro E. P., Kawaguchi M., et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation: 2001; 104 13 1464 1470
213. Salama M. E., EL-Damarawi M. A., Salama A. F. A comparison between the impact of two different exercise protocols on advanced glycation end products in type 2 diabetic rats. Life Sci J: 2013; 10 3 860 869
214. Choi K. M., Han K. A., Ahn H. J., et al. Effects of exercise on sRAGE levels and cardiometabolic risk factors in patients with type 2 diabetes: a randomized controlled trial. J Clin Endocrinol Metab: 2012; 97 10 3751 3758
215. Lam J. K., Wang Y., Shiu S. W., Wong Y., Betteridge D. J., Tan K. C. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE). Diabet Med: 2013; 30 6 702 709
216. Irani M., Minkoff H., Seifer D. B., Merhi Z. Vitamin D increases serum levels of the soluble receptor for advanced glycation end products in women with PCOS. J Clin Endocrinol Metab: 2014; 99 5 E886 E890
217. Tam H. L., Shiu S. W., Wong Y., Chow W. S., Betteridge D. J., Tan K. C. Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. Atherosclerosis: 2010; 209 1 173 177
218. Nozue T., Yamagishi S-I, Takeuchi M., et al. Effects of statins on the serum soluble receptor forms of advanced glycation end products and the association with coronary atherosclerosis in patients with angina pectoris. Int J Clin Metab Endocrin.: 2014; 4 47 62
219. Forbes J. M., Thorpe S. R., Thallas-Bonke V., et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol: 2005; 16 8 2363 2372
220. Plenge J. K., Hernandez T. L., Weil K. M., et al, Simvastatin lowers C-reactive protein within 14 days: An effect independent of low density lipoprotein cholesterol reduction. Circulation: 2002; 106 1447 1452
221. Azen S. P., Qian D., Mack W. J., et al. Effect of supplementary antioxidant vitamin intake on carotid arterial wall intima-media thickness in a controlled clinical trial of cholesterol lowering. Circulation: 1996; 94 10 2369 2372
222. Kritchevsky S. B., Shimakawa T., Tell G. S., et al. Dietary antioxidants and carotid artery wall thickness. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation: 1995; 92 8 2142 2150
223. Devaraj S., Tang R., Adams-Huet B., et al. Effect of high-dose α-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease. Am J Clin Nutr: 2007; 86 5 1392 1398
224. McQuillan B. M., Hung J., Beilby J. P., Nidorf M., Thompson P. L.; The Perth Carotid Ultrasound Disease Assessment Study (CUDAS). Antioxidant vitamins and the risk of carotid atherosclerosis. The Perth Carotid Ultrasound Disease Assessment study (CUDAS). J Am Coll Cardiol: 2001; 38 7 1788 1794
225. Karppi J., Kurl S., Ronkainen K., Kauhanen J., Laukkanen J. A. Serum carotenoids reduce progression of early atherosclerosis in the carotid artery wall among Eastern Finnish men. PLoS ONE: 2013; 8 5 e64107
226. Gale C. R., Ashurst H. E., Powers H. J., Martyn C. N. Antioxidant vitamin status and carotid atherosclerosis in the elderly. Am J Clin Nutr: 2001; 74 3 402 408
227. Tomeo A. C., Geller M., Watkins T. R., Gapor A., Bierenbaum M. L. Antioxidant effects of tocotrienols in patients with hyperlipidemia and carotid stenosis. Lipids: 1995; 30 12 1179 1183
228. Aviram M., Rosenblat M., Gaitini D., et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr: 2004; 23 3 423 433
229. Burton G. W., Ingold K. U. Vitamin E: application of the principles of physical organic chemistry to the exploration of its structure and function. Acc Chem Res: 1986; 19 194 201
230. Bowry V. W., Ingold K. U., Stocker R. Vitamin E in human low-density lipoprotein. When and how this antioxidant becomes a pro-oxidant. Biochem J: 1992; 288 Pt 2 341 344
231. Doba T., Burton G. W., Ingold K. U. Antioxidant and co-antioxidant activity of vitamin C. The effect of vitamin C, either alone or in the presence of vitamin E or a water-soluble vitamin E analogue, upon the peroxidation of aqueous multilamellar phospholipid liposomes. Biochim Biophys Acta: 1985; 835 2 298 303
232. Abbott A. L. Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis: results of a systematic review and analysis. Stroke: 2009; 40 10 e573 e583
233. Selim M. H., Molina C. A. Medical versus surgical treatment of asymptomatic carotid stenosis: the ever-changing nature of evidence-based medicine. Stroke: 2011; 42 4 1156 1157